Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

Our proprietary delivery system allows a class of existing high potency oncology drugs to be dosed orally to improve patient outcomes and quality of life.

Our Src Kinase Inhibitors also bind to a novel site on tubulin heterodimers thereby broadening their anti-tumor activity beyond that provided by Src inhibition alone.

Transformative, oncology-focused and highly synergistic pipeline with late stage product candidates.

Important Information

Click Here for Important information for Health Care Providers regarding Sodium Bicarbonate Injection
Click Here for Athenex Anti-Capital Punishment Statement

Athenex IPO on the NASDAQ Stock Market, June 14, 2017

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.

Photography by Christopher Galluzzo / Nasdaq, Inc.
Photography by Christopher Galluzzo / Nasdaq, Inc.
Governor Cuomo Announces Major Expansion of Athenex — Creating 1,400 Jobs in Western New York

Rendering of new 300,000 square foot facility

Athenex (formerly Kinex) to invest $1.62 billion in drug discovery and advanced manufacturing partnership, creating 900 jobs in Dunkirk and 500 jobs in Buffalo over the next ten years.

State investing $225 million to support the Buffalo Medical Innovation and Commercialization Hub and help create new opportunities for the region.

Governor Andrew M. Cuomo recently announced a major expansion of Athenex that will create 1,400 jobs throughout Western New York. This announcement, made possible by a partnership with the SUNY Polytechnic Institute, includes a major expansion of Athenex’s North American headquarters at the Conventus Building in Buffalo, as well as the creation of a state-of-the-art, 300,000 square foot manufacturing facility in Dunkirk.

Read more

Athenex Completes Public/Private Partnership Agreement with Chongqing, China To Construct Two New Pharmaceutical Manufacturing Plants

Athenex recently announced the completion and execution of a definitive agreement with the Banan District in Chongqing, China to construct two separate pharmaceutical manufacturing plants on Banan sites already identified and selected by Athenex management. Under the terms of the agreement, Banan will provide the funding for the land and construction of the manufacturing plants according to Athenex specifications, and Athenex will equip the facilities.

Read more

Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer

Plans for Second Interim Analysis in Third Quarter of 2018 BUFFALO, N.Y., Feb. 15, 2018 (GLOBE NEWSWIRE) — Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the enrollment of patients is on target for the Company to be able to conduct a second interim analysis in the Oraxol KX-ORAX-001 Phase III clinical trial in the third quarter o… Read more

Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis

BUFFALO, N.Y., Feb. 14, 2018 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced early completion of patient enrollment for both Phase III clinical studies of KX2-391 Ointment for actinic keratosis indications months ahead of schedule. Actinic keratosis is a common skin condition that is induced through ultra-vio… Read more